BN Business News
Ajouter votre entreprise →
Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.

Entreprise · 08/12/20231 min de lecture

Bayer HealthCare Pharmaceuticals Inc., et al.; Withdrawal of Approval of CIPRO (Ciprofloxacin Hydrochloride) Oral Tablet, Equivalent to 100 Milligrams Base, and Five Generic Ciprofloxacin Hydrochloride, Oral Tablet, Equivalent to 100 Milligrams Base Drug Products

Traduction automatique locale · Langue originale de la source

Résumé

The Food and Drug Administration (FDA or the Agency) is withdrawing the approval of CIPRO (ciprofloxacin hydrochloride (HCl)) oral tablet, equivalent to (EQ) 100 milligrams (mg) base under new drug application (NDA) 019537 and five generic ciprofloxacin HCl, oral tablet, EQ 100 mg base products which referenced it as their basis of submission. The holders of the applications requested withdrawal of the 100 mg strength products and waived their opportunity for a hearing.

Langue originale de la source: Federal Register — Food and Drug AdministrationOuvrir le communiqué original →

Explorer les analyses

Analyses business →